Ventracor's Clinical Trial Programme In US Gaining...

Ventracor's Clinical Trial Programme In US Gaining Traction

Sydney, May 29, 2007 (ACN Newswire) - Ventracor (ASX: VCR) (ADR: VTCRY) is about to commence two major clinical trials in the US after the company successfully completed a Feasibility Trial. The first is a Bridge to Transplant (BTT) Pivotal Trial for patients on the transplant list; the FDA recently approved the start of this trial. The trial will be conducted on approximately 140 patients in up to 40 centres. The second is the Destination Therapy Trial (DT) for patients who are not on the transplant list. The trial design is innovative and separated into two modules and the primary outcome is stroke-free survival (refer to full document link below).

The company will apply for a patent surrounding this trial design and potentially could reduce the time for approval by 18 months.

Ventracor recently announced that 100 implants had been performed in Australia, Europe and the US. Ventracor gained its European approval in December 2006. The trial results showed an 83% success rate in the trial, better than the recently announced 75% success from market leader Thoratec for its second-generation device.

ABN AMRO has reviewed the competitive landscape for third-generation heart assist devices (refer to full document for more details). Of the third-generation device companies, Ventracor is more advanced in the US than its competitors in terms of undertaking clinical trials. In Europe, Ventracor is one of three third-generation devices approved for sale.

ABN AMRO's DCF based valuation is A$1.41 (from A$1.50) following a change to later-year forecasts. The assumptions are a risk free rate of 5.75%, a WACC of 15.8% and terminal growth rate of 3.0%. Our price target remains A$1.20, a 15% discount to the valuation to reflect a short term view on successfully achieving milestones. The downside risks to our price target revolve around delays that may occur during the approval process and a slower development of the LVAD market, which is still in its infancy.

For the full ABN AMRO report, please download from the link below;

http://www.acnnewswire.net/publicdocs/vcr70423.pdf


About Ventracor Limited

Ventracor Limited is a global medical device company that has developed an implantable blood pump, the VentrAssist(TM) left ventricular assist system (LVAS) for patients in cardiac failure. The company hopes to bring the VentrAssist(TM) to the global market in record time, and expects to obtain a significant share of the huge potential market.

Contact
Ventracor
126 Greville Street
Chatswood NSW 2067
Sydney Australia
T: +61 2 9406 3100
F: +61 2 9406 3101
E: [email protected]
W: www.ventracor.com

USA
Ventracor Inc.
101 Lincoln Centre Drive
Suite 420
Foster City CA 94404
T: +1 866 882 5089 (US Toll Free)
+1 650 356 5900 (Outside US)
F: +1 650 356 5901

Europe
Ventracor (UK) Limited
10 Wellington Street
Cambridge CB1 1HW, UK
T: +33 6 9927 0706
F: +33 4 2623 6711


Ventracor Limited
Edit/Change PreferencesBookmark XML RSS2.0

May 29, 2007
Source: Ventracor Limited(ASX: VCR) (ZOBEX: VTR) (OTCBB: VTCRY) (PNK: VTCRY)
From the Asia Corporate News Network
http://www.acnnewswire.net
Topic: Research / Industry Report
Sectors: Clinical Trials, Medical Equipment